Maintenance therapy in multiple myeloma
The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide). When conven...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2009-08-01
|
| Serija: | Hematology Reports |
| Teme: | |
| Online pristup: | http://www.pagepress.org/journals/index.php/hr/article/view/1105 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|